Niveaux de plasma de la secretagogine (SCGN) et leur association avec le comportement cognitif et social chez les enfants avec un diagnostic de trouble du spectre de l'autisme (TSA)

Aperçu: G.M.

L'étude analyse les niveaux plasmatiques de sécrétagogine (SCGN) chez les enfants avec un diagnostic de troubles du spectre de l'autisme (TSA) comparé à un groupe sans TSA apparié selon l'âge et le sexe et à son association avec les comportements cognitifs et sociaux en utilisant l'échelle d'évaluation de l'autisme chez l'enfant (CARS) et l'échelle de réactivité sociale (SRS).

Les faibles concentrations plasmatiques de SCGN chez les enfants atteints de TSA indiquent probablement que le SCGN pourrait être impliqué dans la pathogenèse de l'autisme. Cependant, ces données doivent être traitées avec prudence jusqu'à ce que d'autres recherches soient effectuées en utilisant des tailles d'échantillon plus importantes pour déterminer si la diminution des niveaux de SCGN plasmatique est une simple conséquence de l'autisme ou joue un rôle pathogène dans le trouble.  

 

J Coll Physicians Surg Pak. 2017 Apr;27(4):222-226. doi: 2594.

Secretagogin (SCGN) Plasma Levels and their Association with Cognitive and Social Behavior in Children with Autism Spectrum Disorder ASD)

Alhowikan AM¹, -Ayadhi LA¹, Halepoto DM¹.

Author information

1

Department of Physiology, Autism Research and Treatment Center, Al-Amodi Autism Research Chair, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia.

Abstract

OBJECTIVE:

To investigate the secretagogin (SCGN) plasma levels in children with autism spectrum disorder (ASD) compared to age and gender-matched healthy control, and its association with cognitive and social behaviors by using childhood autism rating scale (CARS) and social responsiveness scale (SRS).

STUDY DESIGN:

Case-control study.

PLACE AND DURATION OF STUDY:

Autism Research and Treatment Center, Al-Amodi Autism Research Chair, Department of Physiology, Faculty of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia, from October 2015 to May 2016.

METHODOLOGY:

SCGN levels were determined in the plasma of thirty-seven (37) autistic children using enzyme-linked immunosorbent assay (ELISA), categorized as mild-moderate and severe as indicated by their CARS scores and compared with thirty (30) age and gender-matched control samples. Correlation between SCGN levels and different cognitive and social behavior scales (CARS and SRS) was determined by Spearman's correlation coefficient (r).

RESULTS:

The results indicated that autistic children (n=37) had significantly (p= 0.005) lower plasma level of SCGN {45.7 (26.2) ng/ml [median (IQR)]} than those of healthy controls {n=30, 70.8 (48.6) ng/ml [median (IQR)]}. Children with severe (n=28, 76%) as well as mild to moderate autism (n=09, 24%) also exhibited significantly lower SCGN levels {47.5 (27) ng/ml [median (IQR)], p =0.014} and {45.7 (16.6) ng/ml [median (IQR)], p = 0.02)}, respectively than healthy controls {n=30, 70.8 (48.6) ng/ml [median (IQR)]}. However, there was no significant difference between the SCGN levels of children with mild to moderate and severe autism (p = 0.66). Spearman's correlation coefficient (r) was used to determine the relationships between SCGN levels and different variables (CARS, SRS). However, the results showed no significant correlation between SCGN and these scales. (CARS, r=-0.03, p=0.86; SRS, r=0.21, p=0.20).

CONCLUSION:

The low SCGN plasma levels in children with ASD probably indicate that SCGN might be implicated in the pathogenesis of autism. However, these data should be treated with caution until further investigations are performed using larger sample sizes to determine whether the decrease in plasma SCGN levels is a mere consequence of autism or it plays a pathogenic role in the disease.

PMID:28492151

DOI: 2594